Cargando…
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
In the last 20 years, dendritic cells (DCs) have been largely used as a platform for therapeutic vaccination in cancer patients. However, despite its proven safety and ability to induce cancer specific immune responses, the clinical benefits of DC-based immunotherapy are currently very limited. Thus...
Autores principales: | Mookerjee, Ananda, Graciotti, Michele, Kandalaft, Lana E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356194/ https://www.ncbi.nlm.nih.gov/pubmed/30621204 http://dx.doi.org/10.3390/cancers11010040 |
Ejemplares similares
-
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018) -
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019) -
Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform
por: Ahmed, Rita, et al.
Publicado: (2020) -
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
por: Graciotti, Michele, et al.
Publicado: (2017) -
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
por: Martin Lluesma, Silvia, et al.
Publicado: (2018)